Chengxiang Wang

Chengxiang Wang

Auto-generated profile, based on publicly available information

Chengxiang Wang

Beijing University of Chinese Medicine, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2019 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
FYFei Yang
Fei Yang
MLMingyu Liu
Mingyu Liu
NQNankun Qin
Nankun Qin
SLShuangshuang Li
Shuangshuang Li
MYMengqi Yu
Mengqi Yu
QMQun Ma
Qun Ma
Hyperuricemia as a metabolic disease is usually associated with lipid metabolic disorder. The purpose of this study is to identify potential lipid biomarkers and provide the evidence for the relationship between hyperuricemia and lipid-related diseases. Lipidomics-a specialized study of lipid metabolites-has become a highly sensitive and powerful tool for biomarker discovery. In this work, an ultra-performance liquid chromatography-quadruole-time-of-flight tandem mass spectrometry (UPLC-Q-TOF/MS)-based on Lipidomics approach was employed to investigate serum samples from potassium oxonate-treated rats to find potential biomarkers. Principal component analysis (PCA) was used to analyze the MS data to assess the establishment of hyperuricemia model. Orthogonal partial least-squares discriminant analysis (OPLS-DA) in combination with independent samples t-test was performed for biomarker selection and identification. Thirteen potential biomarkers in rat serum were identified in the screen, and two abnormal metabolism pathways were found, namely glycerolphospholipid metabolism and glycosylphosphatidylinositol-anchored protein biosynthesis. In this work, the Lipidomics approach based on UPLC-Q-TOF/MS was employed to investigate serum metabolic changes in the rat model, 13 potential biomarkers related to hyperuricemia were identified, primarily involved in glycerolphospholipid metabolism and glycosylphosphatidylinositol-anchored protein biosynthesis. Abnormal glycerophospholipid metabolism pathway may be associated with lipid metabolism disorder caused by hyperuricemia, while the relationship between hyperuricemia and glycosylphosphatidylinositol-anchored protein biosynthesis needs further study.

12 June 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
NQNankun Qin
Nankun Qin
YJYue Jiang
Yue Jiang
WSWenjun Shi
Wenjun Shi
LWLiting Wang
Liting Wang
LKLingbo Kong
Lingbo Kong
QMQun Ma
Qun Ma
Hyperuricemia (HUA) as a metabolic disease is closely associated with metabolic disorders. The etiology and pathogenesis of HUA are not fully understood, so there is no radical cure so far. Metabolomics, a specialized study of endogenous small molecule substances, has become a powerful tool for metabolic pathway analysis of selected differential metabolites, which is helpful for initially revealing possible development mechanisms of various human diseases. Twenty HUA patients and 20 healthy individuals participated in the experiment, and ultrahigh performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF/MS) was employed to investigate serum samples to find differential metabolites. The statistical techniques used were principal component analysis and orthogonal partial least-squares discriminant analysis. The differences in metabolomics results of samples after pretreatment with different solvents were compared, 38, 20, 26, 28, 33, 50, and 40 potential differential metabolites were found, respectively, in HUA patient samples, and each group involved different metabolic pathways. Repetitive metabolites were removed, 138 differential metabolites in HUA serum were integrated for analysis, and the human body was affected by 7 metabolic pathways of glycerophospholipid metabolism, sphingolipid metabolism, arachidonic acid metabolism, linoleic acid metabolism, phenylalanine metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, and α-linolenic acid metabolism. In this work, the metabolomics approach based on UPLC-Q-TOF/MS was employed to investigate serum metabolic changes in HUA patients, 138 potential differential metabolites related to HUA were identified, which provided associations of lipids, amino acids, fatty acids, organic acids, and nucleosides profiles of HUA individuals. Metabolic pathways involved in glycerophospholipid metabolism, sphingolipid metabolism, arachidonic acid metabolism, linoleic acid metabolism, phenylalanine metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, and a-linolenic acid metabolism shed light on the understanding of the etiology and pathogenesis process of HUA.

20 March 2020 in RSC Advances
Verified
Journal Article
Open access
PDF file
GYGuijuan Yue
Guijuan Yue
CWChengxiang Wang
Chengxiang Wang
BLBo Liu
Bo Liu
MWMangang Wu
Mangang Wu
YHYuangyuan Huang
Yuangyuan Huang
QMQun Ma
Qun Ma
Doxorubicin (DOX) is one of the core drugs in triple-negative breast cancer (TNBC) chemotherapy, but its resistance has severely limited its clinical application. Our previous study found that astragaloside IV (AS-IV) has a good reversal effect on doxorubicin resistance. In order to encapsulate DOX and AS-IV simultaneously, a new liposome-targeted co-delivery system co-modified by the folate ligand (FA) and octa-arginine polypeptide (R8) (FA-R8-LPs, for short) was prepared. In this co-delivery system, R8 not only served as a bond connecting the FA to the liposome, but also played the role of cell penetrating peptides (CPPs). This design effectively increased the tumor targeting and cellular uptake capacity of liposomes. The results of the cytotoxicity test indicated that FA-R8-LPs significantly inhibited the proliferation of the DOX resistant cell line MDA-MB-231/DOX in vitro. In nude mice tumor models inoculated with MDA-MB-231/DOX cells, FA-R8-LPs significantly inhibited tumor growth, and overcame doxorubicin resistance, exhibiting excellent antitumor effects. This study demonstrates that liposome-targeted co-delivery systems based on FA and R8 double modifying may provide a new and effective strategy for the treatment of TNBC, which is of great significance for drug combination.

13 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
GCGuo Chao Chen
Guo Chao Chen
WZWanqiao Zhang
Wanqiao Zhang
LKLingbo Kong
Lingbo Kong
CWChengxiang Wang
Chengxiang Wang
XLXiaojing Lai
Xiaojing Lai
QMQun Ma
Qun Ma
Pseudomonas aeruginosa (PA), a Gram‐negative bacterium, has a high detection rate in hospital‐acquired infections. Recently, the frequent appearance of multidrug‐resistant (MDR) PA strain with high morbidity and mortality rates has aggravated the difficulty in treating infectious diseases. Due to its multiple resistance mechanisms, the commonly used antibiotics have gradually become less effective. Qiguiyin decoction (QGYD) is a clinically experienced prescription of Chinese herbal medicine, and its combined application with antibiotics has been confirmed to be effective in the clinical treatment of MDR PA infection, which could be a promising strategy for the treatment of drug‐resistant bacterial infections. However, the mechanism of QGYD restoring antibiotics susceptibility to MDR PA remains unclear. In the present study, we investigated the effects of QGYD and levofloxacin (LEV) singly or in combination on MDR PA‐induced pneumonia rat models. Further analysis was carried out in the serum differential expression profiles of inflammatory cytokines by cytokine antibody array. Besides, the lung TLR4/MyD88/NF‐κB signaling pathway was detected by RT‐qPCR. Our results showed that based on the treatment of MDR PA‐infected rat model with LEV, the combination of QGYD improved the general state and immune organ index. Furthermore, it moderately increased the expressions of proinflammatory cytokines including IL‐1β, IL‐6, and TNF‐α in the early stage of infection and decreased their release rapidly in the later stage, while regulated the same phase change of anti‐inflammatory cytokine IL‐10. In addition, the adhesion molecule ICAM‐1 was significantly downregulated after QGYD combined with LEV treatment. Moreover, the mRNA expressions of TLR4, MyD88, NF‐κB, and ICAM‐1 were significantly downregulated. These results indicated that the mechanism of QGYD restoring LEV susceptibility to MDR PA was related to its regulation of inflammatory cytokines and the TLR4/MyD88/NF‐κB signaling pathway, which provides theoretical support for the clinical application of QGYD combined with LEV therapy to MDR PA infection.

13 November 2026 in Medicine
Verified
Journal Article
Open access
TCTianyun Chen
Tianyun Chen
CWChengxiang Wang
Chengxiang Wang
Observational studies have linked arthritis and asthma, but establishing causality is challenging due to confounding. We analyzed 30,001 adults from the National Health and Nutrition Examination Survey (2003–2018) using survey-weighted logistic regression to assess observational associations. To infer causality, we conducted a two-sample Mendelian randomization analysis using publicly available genetic data. In the observational analysis, arthritis was significantly associated with a higher risk of asthma (adjusted odds ratio = 1.96, 95% confidence interval = 1.75–2.19), with similar findings for rheumatoid arthritis (RA) and osteoarthritis (OA). Mendelian randomization analysis provided evidence for a positive causal effect of genetic predisposition to RA on asthma (inverse-variance weighted odds ratio = 1.037, 95% confidence interval = 1.007–1.068), but found no significant causal effect for OA. This study provides dual evidence supporting a significant and potentially causal relationship between RA and asthma. In contrast, the association with OA appears to be noncausal, likely driven by confounding factors.